Success! You're on the list.

Success! You're on the list.

Tridek-One raises $16.1M to develop first-in-class tech for immune balance


Tridek-One SAS (the ‘Company’), a biotech startup specialising in the research and development of CD31 agonists to restore immune balance, has raised $16.1M in financing led by Swiss VC Pureos Bioventures, with participation from new investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), as well as historical investors AdBio partners and Advent Life Sciences. 

The funds will be used primarily to identify development candidates for auto-immune diseases, conduct IND-enabling studies, and expand the organisation. The company previously raised $3.02M in a first round of funding in 2019 with AdBio partners (FR) and Advent Life Sciences (UK).

New joinees

Tridek-One also named Laurence de Schoulepnikoff as CEO and Erik van den Berg as Chairman of the Board of Directors.

Laurence is a pharma and biotech executive with extensive experience in transactions and R&D operations. She has experience working in VC-funded biotech start-ups, mid-size private companies, and large corporate organisations. Laurence joins Tridek-One from AMAL Therapeutics, a Swiss biotechnology company focused on therapeutic cancer vaccines, where she served as a chief business officer and chief operating officer for the last three years. Boehringer Ingelheim purchased AMAL in 2019. Laurence will now be in charge of Tridek-strategy One’s and development, as well as its overall organisation.

Tridek-One, founded in 2018 by Dr. Giuseppina Caligiuri and Pr. Antonino Nicoletti, researchers at INSERM Unit 1148 (Paris, France), is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases with the support of historical investor AdBio partners. The company creates immune checkpoint agonists to help patients with auto-immune diseases rebalance their immune systems.

Previous funding

The company had raised $3.02M in a first funding round in 2019 with the support of two venture funds, AdBio partners and Advent Life Sciences.

“I am delighted and grateful to have the opportunity to lead Tridek-One as we plan to reach important preclinical milestones and build a first-class biotech organization for the treatment of auto-immune diseases,” said Laurence de Schoulepnikoff, CEO of Tridek-One.

“It is a pleasure to join as chairman whilst the company is building a great team, with a professional syndicate of international investors committing to decades of research by the team of Dr. Giuseppina Caligiuri and Pr Antonino Nicoletti,” said Erik van den Berg, the chairman of the board at Tridek-One.

“There is still an important, unsatisfied medical need in many auto-immune diseases. Agonizing immune inhibitory receptors like CD31 has the potential to rebalance the immune system without being more broadly immunosuppressive. We are excited to further translate this concept with Tridek-One through its discovery and preclinical stages,” commented Klaus Breiner, managing partner at Pureos Bioventures.

“AdBio partners was the founding investor in Tridek-One in 2018; we were further joined by Advent Life Sciences. We are delighted to welcome additional investors who believe in the breakthrough innovation developed by this cutting-edge company. This confirms our initial decision to be company founder and builder,” added Alain Huriez, general partner at AdBio partners.

“To be accompanied by investors who believe in our project is a fantastic opportunity. This will enable us to accelerate our work to identify and develop first-in-class immune checkpoint agonists capable of controlling serious inflammatory diseases,” concluded Dr. Giuseppina Caligiuri and Pr. Antonino Nicoletti, scientific founders of Tridek-One.

Related Posts

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you